Chris J Bushe

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 27:358-65. 2013
  2. pmc A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with nationa
    Nicola Savill
    Medical Department, Eli Lilly and Company Ltd, Lilly House, Priestley Road, Basingstoke, Hants, RG24 9NL, UK
    Child Adolesc Psychiatry Ment Health 6:2. 2012
  3. doi request reprint Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, United Kingdom
    J Clin Psychiatry 73:e749-55. 2012
  4. pmc Mortality in schizophrenia: a measurable clinical endpoint
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 24:17-25. 2010
  5. doi request reprint A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Ann Clin Biochem 47:292-300. 2010
  6. doi request reprint Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies
    C J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Int J Clin Pract 63:1743-61. 2009
  7. doi request reprint Schizophrenia and breast cancer incidence: a systematic review of clinical studies
    Chris J Bushe
    Eli Lilly and Company Ltd, Lilly House, Priestly Road, Basingstoke RG24 9NL, UK
    Schizophr Res 114:6-16. 2009
  8. doi request reprint Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
    C Bushe
    Eli Lilly and Company, Basingstoke, UK
    J Psychopharmacol 24:1001-9. 2010
  9. pmc Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation
    Chris J Bushe
    Eli Lilly and Company Ltd, Adelaide Road, Dublin, Ireland
    BMC Psychiatry 8:76. 2008
  10. ncbi request reprint Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
    Chris Bushe
    Eli Lilly and Co Ltd, Basingstoke, University of Southampton, UK
    Br J Psychiatry Suppl 47:S67-71. 2004

Detail Information

Publications20

  1. doi request reprint Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 27:358-65. 2013
    ..BMI has an association with the likelihood of weight gain or loss and should be considered in analyses of antipsychotic weight change...
  2. pmc A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with nationa
    Nicola Savill
    Medical Department, Eli Lilly and Company Ltd, Lilly House, Priestley Road, Basingstoke, Hants, RG24 9NL, UK
    Child Adolesc Psychiatry Ment Health 6:2. 2012
    ..abstract:..
  3. doi request reprint Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, United Kingdom
    J Clin Psychiatry 73:e749-55. 2012
    ..Weight change data from randomized clinical trials are often of limited duration and trials do not always report a full range of clinically relevant categorical end points...
  4. pmc Mortality in schizophrenia: a measurable clinical endpoint
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 24:17-25. 2010
    ....
  5. doi request reprint A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Ann Clin Biochem 47:292-300. 2010
    ..Physicians must balance the benefits and risks of treatment when determining appropriate therapy for individual patients...
  6. doi request reprint Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies
    C J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Int J Clin Pract 63:1743-61. 2009
    ....
  7. doi request reprint Schizophrenia and breast cancer incidence: a systematic review of clinical studies
    Chris J Bushe
    Eli Lilly and Company Ltd, Lilly House, Priestly Road, Basingstoke RG24 9NL, UK
    Schizophr Res 114:6-16. 2009
    ..We undertook a systematic review of published data to investigate possible reasons for the variable findings...
  8. doi request reprint Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
    C Bushe
    Eli Lilly and Company, Basingstoke, UK
    J Psychopharmacol 24:1001-9. 2010
    ..9%; QUE 31.4%), but after 2 weeks of treatment prolactin values had reverted to normal for nearly all patients (OLZ 100%; QUE 99.4%). There were no significant treatment differences in any variable between cohorts...
  9. pmc Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation
    Chris J Bushe
    Eli Lilly and Company Ltd, Adelaide Road, Dublin, Ireland
    BMC Psychiatry 8:76. 2008
    ..There is no data on these programmes in acutely unwell inpatients whom may be the major beneficiaries...
  10. ncbi request reprint Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
    Chris Bushe
    Eli Lilly and Co Ltd, Basingstoke, University of Southampton, UK
    Br J Psychiatry Suppl 47:S67-71. 2004
    ..A number of studies have examined the prevalence of diabetes mellitus and impaired glucose tolerance in general populations and in those with schizophrenia and other forms of serious mental illness...
  11. ncbi request reprint The role of lifestyle interventions and weight management in schizophrenia
    Chris Bushe
    Eli Lilly and Company Limited, Basingstoke, UK
    J Psychopharmacol 19:28-35. 2005
    ..Weight management and lifestyle advice should be routinely offered to all schizophrenia subjects...
  12. ncbi request reprint The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?
    Chris Bushe
    Eli Lilly and Company Limited, Basingstoke, UK
    J Psychopharmacol 19:76-83. 2005
    ....
  13. ncbi request reprint Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials
    Chris J Bushe
    Eli Lilly and Co Ltd, Basingstoke, United Kingdom
    J Clin Psychiatry 68:1682-90. 2007
    ..Prospective data collected from randomized controlled trials may reduce such biases. As no single trial has glucose comparisons as a primary endpoint, we undertook a systematic review of available data...
  14. doi request reprint Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program
    Richard I G Holt
    Developmental Origins of Health and Disease Division, School of Medicine, University of Southampton, United Kingdom
    J Clin Psychiatry 71:800-5. 2010
    ..Obesity is 2 to 3 times more common among people with severe mental illness and has adverse effects on physical and psychological health. We report the experience from the first 8 years of a self-referring weight management clinic...
  15. ncbi request reprint Diabetes and schizophrenia 2005: are we any closer to understanding the link?
    Richard I G Holt
    Developmental Origins of Health and Disease Division, University of Southampton, Southampton, UK
    J Psychopharmacol 19:56-65. 2005
    ..Traditional risk factors most probably account for much of the diabetes seen in schizophrenia populations, suggesting that routine screening and aggressive risk factor management are especially important in this patient group...
  16. ncbi request reprint Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
    Chris Bushe
    Eli Lilly and Co Ltd, Basingstoke, UK
    Br J Psychiatry Suppl 47:S87-93. 2004
    ..Most evidence suggesting an association between schizophrenia, antipsychotic medications and diabetes has been based on retrospective studies not controlled for important confounders...
  17. ncbi request reprint Schizophrenia and cancer: in 2010 do we understand the connection?
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, England
    Can J Psychiatry 55:761-7. 2010
    ..Additionally, there have been suggestions that schizophrenia may provide inherent protection against cancer. The goal of this review is to establish, using recent data, the incidence and mortality rates for cancer in schizophrenia...
  18. doi request reprint A review of the association between antipsychotic use and hyperprolactinaemia
    Chris Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 22:46-55. 2008
    ..Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics...
  19. ncbi request reprint Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics
    Chris Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 21:768-73. 2007
    ..Clinicians may be helped by the reporting of such categorical data from clinical trials in addition to mean cohort values of prolactin. Long-term hyperprolactinaemia may be associated with clinical sequeLae in some patients...
  20. doi request reprint Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics
    Chris Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    J Psychopharmacol 22:56-62. 2008
    ..Clinicians may wish to add prolactin measurement to the routine laboratory parameters currently measured for some antipsychotics and should be advised of the potential longer-term consequences of hidden hyperprolactinaemia...